{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,3]],"date-time":"2022-04-03T08:21:51Z","timestamp":1648974111532},"reference-count":3,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2009,12,1]],"date-time":"2009-12-01T00:00:00Z","timestamp":1259625600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,12,3]],"date-time":"2019-12-03T00:00:00Z","timestamp":1575331200000},"content-version":"vor","delay-in-days":3654,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2009,12]]},"DOI":"10.1093\/annonc\/mdp429","type":"journal-article","created":{"date-parts":[[2009,9,15]],"date-time":"2009-09-15T00:13:02Z","timestamp":1252973582000},"page":"2019","source":"Crossref","is-referenced-by-count":1,"title":["Bone morphogenetic proteins and zoledronic acid"],"prefix":"10.1016","volume":"20","author":[{"given":"U.","family":"Sahin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Alkan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.","family":"Altundag","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1093\/annonc\/mdp429_bb0010","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1093\/annonc\/mdp378","article-title":"Antitumoral effect of the bisphosphonate zoledronic acid against visceral metastases in an adrenocortical cancer patient","volume":"20","author":"Boudou-Rouquette","year":"2009","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdp429_bb0015","doi-asserted-by":"crossref","first-page":"5784","DOI":"10.1158\/0008-5472.CAN-08-4428","article-title":"Bone morphogenetic proteins 2 and 5 are down-regulated in adrenocortical carcinoma and modulate adrenal cell proliferation and steroidogenesis","volume":"69","author":"Johnsen","year":"2009","journal-title":"Cancer Res"},{"key":"10.1093\/annonc\/mdp429_bb0020","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.bone.2003.08.013","article-title":"The nitrogen-containing bisphosphonate, zoledronic acid, increases mineralisation of human bone-derived cells in vitro","volume":"34","author":"Pan","year":"2004","journal-title":"Bone"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S092375341939876X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S092375341939876X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/20\/12\/2019\/556841\/mdp429.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,23]],"date-time":"2021-06-23T08:24:06Z","timestamp":1624436646000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S092375341939876X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,12]]},"references-count":3,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2009,12]]}},"alternative-id":["S092375341939876X"],"URL":"https:\/\/doi.org\/10.1093\/annonc\/mdp429","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2009,12]]}}}